Authorized Shares - 3,000,000,000
Outstanding Shares - 628,949,077
Creative Medical Technology Holdings Files Patent on Anti-aging Technology Using AmnioStem Stem Cells PHOENIX, May 8, 2018
Creative Medical Technology Holdings announced today filing of patent application number 62663912 covering the use of its AmnioStemTM stem cells as a means of reducing/reversing natural aging.
Previous studies by the Company have demonstrated that AmnioStemTM cells secrete factors that are capable of rejuvenating aged cells. By encapsulating the cells outside of the body, so that the cells are in contact with the patient's circulation, the cells are permitted to secrete factors that may reduce aging, without having to inject the cells in the patient.
The concept of using cells that are growing outside of the body as a means of modifying physiological activities has previously been performed and appears feasible. Specifically, similar approaches to mixing patient blood with cells outside of the body have previously been attempted in the area of liver failure. A clinical trial demonstrated feasibility of using cell culture of hepatocytes to act as a "liver assist device". These devices are currently in Phase 3 of clinical trials1,2.
The filed patent describes a similar approach to those used in liver failure, with the exception that instead of using hepatocytes outside of the body, the device uses AmnioStemTM amniotic fluid derived stem cells.
"Previous studies from Stanford University3 and Harvard University4 have shown that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice induce an anti-aging/rejuvenating effects on organs/tissues of aged mice. Through this patent, we are aiming to recapitulate this effect, in an ethical and technically feasible manner." Said Dr. Thomas Ichim, the Company's Chief Scientific Officer. "What is stunning about the AmnioStemTM stem cell, which was licensed by the Company from the University of California San Diego, is that it possesses many regenerative features but is collected from non-controversial sources."
The AmnioStemTM stem cell is derived from amniotic fluid during the process of amniocentesis. Amniotic fluid is typically considered medical waste. Scientists at University of California San Diego have developed means of extracting and growing stem cells from the amniotic fluid. These stem cells have been published to be capable of treating animal models of numerous diseases including stroke5, heart attack6, liver failure7, colitis8, diabetes9, emphysema10, and kidney injury11. An important activity of amniotic fluid stem cells is that cells derived from one person can be used to treat other people, making them "universal donor" stem cells.
"The concept of using young blood to stimulate regeneration in aged individuals is attracting much attention in the area of regenerative medicine. I am enthusiastic about the approach being developed by Creative Medical Technology Holdings, which overcomes some of the important roadblocks that prevent implementation of this novel and promising approach," said Amit Patel, MD, MS, Chief of Cardiothoracic Surgery University of Miami and coinventor of the patent.
"At Creative Medical Technology Holdings we are committed to advancing regenerative medicine to various areas of human suffering. In contrast to other conditions, aging will occur in everyone," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "While the field of anti-aging medicine is filled with various false hopes and hype, we are attempting to address this problem cautiously and methodologically through testing our technology for safety and efficacy.'
"Our goal is to continue to internally develop and patent technology in the regenerative medicine space and to broaden our patent portfolio for future commercialization by the company and/or with other life science companies with complementary technology."
"Urologist to the Stars" Dr. Alexander Gershman to attend American Urological Association conference to discuss the CaverStem™ Stem Cell Procedure for Drug Refractory Erectile Dysfunction
PHOENIX and LOS ANGELES, May 8, 2018
Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today that Dr. Alexander Gershman will attend the AUA conference on May 19th and 20th with Creative Medical Technology Holdings, Inc. to discuss the CaverStem(TM) procedure from the perspective of a physician treating patients.
Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center, began treating patients with the CaverStem(TM) procedure in December 2017, which involves extraction of a small amount of bone marrow, concentration of bone marrow derived stem cells, and subsequent administration to the patient.
"There is much excitement about stem cells revolutionizing many aspects of medicine. I am enthusiastic to be offering this cutting edge procedure to my patients, for which previous therapies have failed or are too invasive," said Dr. Gershman. "Numerous publications and a recent clinical trial at the Los Angeles Biomedical Institute at Harbor - UCLA Hospital in Torrance, CA, support the safety and feasibility of the CaverStem(TM) procedure. The biological basis of the bone marrow based treatment is that in patients with drug non-responsive erectile dysfunction, there is a deficit in function of smooth muscle and blood vessel cells. By administering the patient's own stem cells we aim to rebuild these damaged tissues, and thereby restore erectile function."
Creative Medical Health Technology Holdings is offering the CaverStem(TM) procedure to selected physicians in the USA, which qualify according to the Company's criteria. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
"We are pleased to have one of the top opinion leaders of the urology community join us, as we present the CaverStem(TM) procedure to the attendees of the American Urological Association conference," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.
To all attendees please visit booth 5870 to meet the CaverStem(TM) team.
Creative Medical Technology Holdings to be Keynote Speaker at Gathering of Health Care Innovators
The Company's Stem Cell Therapies to be Main Subject at Dr. James Veltmeyer's Congressional Health Care Symposium April 12th, 2018
SAN DIEGO, April 12, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today it will be giving the Keynote Address at the Veltmeyer Health Care Innovations Symposium April 12 [th] , 2018 in San Diego, CA. The Symposium is a gathering of medical practitioners, health care administrators, biotech investors, and other professionals, aimed at reducing cost and increasing efficiency of the Health Care System.
"Companies like Creative Medical Technology Holdings are pioneering innovative approaches that address the root cause of disease, using adult stem cells, in contrast to the majority of approaches which treat symptoms and not causes," said Dr. James Veltmeyer, Congressional Candidate for the 52nd District and Organizer of the Symposium. "In order to cause change in the currently ineffective Health Care System, we need to support and accelerate clinical translation of regenerative medicine approaches. I applaud Creative Medical Technology Holdings for using adult stem cell therapy, and going through appropriate clinical trials and peer reviewed scientific processes in development of their clinical and commercialized stem cell technologies."
Creative Medical Technology Holdings has commercialized CaverStem™, a patented, adult stem cell procedure in the urology space. Additionally, the Company is developing its technology licensed from the University of California San Diego in the area of neurodegeneration through its subsidiary CerebroStem LLC and its issued StemSpine™ patent on the treatment of degenerative disc disease with the use of adult stem cells.
"We are proud to be invited to speak at such a prestigious gathering of Health Care professionals and present our journey from bench to bedside in the area of adult stem cells," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "We thank Dr. Veltmeyer for organizing the Symposium and supporting the area of Regenerative Medicine, which we all believe will play a major role in addressing the current Health Care Crisis."
Dr. Veltmeyer was chosen as "Top Doctor" of San Diego and has received numerous endorsements including from State Senator Joel Anderson and Dr. Peter Farrell, Founder and Chairman of Resmed Inc., the manufacturers of CPAP devices with a current market capitalization of $14 billion. https://www.marketwatch.com/story/creative-medical-technology-holdings-to-be-keynote-speaker-at-gathering-of-health-care-innovators-2018-04-12
Creative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem™ Procedure For Erectile Dysfunction At International Urology Conference
PHOENIX, March 26, 2018
PHOENIX, March 26, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) will be exhibiting it's patented CaverStemTM stem cell procedure for erectile dysfunction at the annual American Urological Association (AUA) conference on May 18-21, 2018 in San Francisco.
According to the AUA "Last year's meeting welcomed more than 16,000 attendees from more than 100 countries around the world, underscoring the meeting's value to the global urologic community. This year's meeting will feature more innovative programming and educational offerings than ever before, giving physicians unparalleled access to groundbreaking research, the latest clinical guidelines and the most advanced technologies in urology."
We invite all attendees to visit us at booth 5780
"Our cutting edge technology in autologous stem cell treatment for erectile dysfunction is anticipated to be received by the urologic community with great enthusiasm as our CaverStem TM procedure represents an all-natural alternative for those patients resistant to the use of PDE5 inhibitors such as Viagra and Cialis," said Thomas Ichim PhD, Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.
According to multiple publications, approximately 30% of the 30,000,000 men suffering from erectile dysfunction are resistant to such PDE5 inhibitors.
"Since beginning commercialization of our patented and tested CaverStemTM procedure in November 2017, we have received positive responses from the urology community in the limited cities marketed. We anticipate the introduction of our technology to the attendees of the largest annual urology conference, to promote nationwide interest in CaverStemTM," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
About the CaverStemTM procedure: CaverStem™ is a patented process involving extraction of a small amount of bone marrow from the patient, separating stem cells from the bone marrow using an FDA cleared device, followed by re-administration of the stem cells into the corpus cavernosa of the patient's penis. Two clinical studies have been conducted utilizing patient's own bone marrow stem cells administered into the penis, which demonstrated safety and signals of efficacy.
Creative Medical Technology Holdings Licenses Intellectual Property from Internationally Renowned Neurologist and Creates Neurology Focused Stem Cell Subsidiary
PHOENIX, Feb. 20, 2018
PHOENIX, Feb. 20, 2018 /PRNewswire -- Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of CerebroStem LLC, a majority owned subsidiary focused on developing stem cell therapies for brain injuries and neurodegenerative diseases. The Company's initial focus will be treating radiation induced brain damage, a major cause of cognitive dysfunction in patients with brain cancer who have received radiation therapy.
"The AmnioStem(TM) amniotic stem cell product offers a potent platform for developing second generation stem cell therapies useful for neurodegenerative and other neurological diseases," said Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-Oncology, Providence Saint John's Health Center, who leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute. "I am enthusiastic to combine new treatments and procedures developed by AmnioStem(TM) universal donor cell therapy, which I believe will allow for rapid clinical entry."
Dr. Kesari will serve as the Chief Medical Advisor for CerebroStem LLC. In addition to treating radiation induced brain damage, CerebroStem LLC plans to pursue other areas of brain degeneration including stroke, multiple sclerosis, and Parkinson's Disease.
"The desire of Dr. Kesari to combine his strengths with ours in the area of neurology is a major validation of the potential of the AmnioStem(TM) stem cell," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "For the past 3 years we have been developing amniotic stem cells as a therapeutic product based on their potent regenerative activities, while possessing ability to be used without the need for patient matching. We believe that under Dr. Kesari's guidance, these cells will be capable of addressing numerous unmet medical needs in the area of neurology."
CerebroStem LLC will be led by Dr. Thomas Ichim, currently the Chief Scientific Officer of Creative Medical Technology Holdings Inc, who will serve as President and Chief Scientific Officer. Dr. Ichim has been responsible for 3 FDA cleared Investigational New Drug (IND) Applications in the area of cellular therapy and is inventor of over 100 patents and patent applications.
"It is my honor to implement the vision of Dr. Kesari in bringing hope to patients with neurological conditions for which currently there is little or no hope," said Dr. Ichim. "Having previously taken cellular products through the FDA process, and to acquisition, I am exciting to be working at translating these new ideas into patient treatments." https://www.otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-Licenses-Intellectual-Property-from-Internationally-Renowned-Neurologist-and-Create?id=183819
Stem Cells as Medicine: The Promise of Universal Donor Adult Stem Cells Continues to Attract Optimism
PHOENIX, Dec. 20, 2017
PHOENIX, Dec. 20, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc (OTCQB:CELZ) provides the following discussion on a recent US News and World Report article addressing advances of adult stem cells and its own patented stem cell technologies.
Stem cells are broadly categorized into "embryonic" and "adult" stem cells. Embryonic stem cells are derived from fertilized eggs and hold potential to generate every major tissue in the body. Unfortunately, embryonic stem cells are difficult to control due to their very immature state. This limits their ability to be used in patients, which has accounted for a lack of commercial success. In contrast, adult stem cells, which are classified as every type of stem cell that is not embryonic, are the basis of the technology of the two publicly traded biotech companies referenced in the article, Mesoblast and Athersys. Currently, Mesoblast is developing stem cells based on bone marrow stem cells from donors, primarily for treating heart failure, which is in the most advanced phases of clinical trials, termed Phase III. Additionally, Athersys is also using bone marrow derived stem cells from donors, primarily for use in stroke, which is also in Phase III clinical trials.
"We at Creative Medical Technologies are encouraged by this promising article that highlights the important advances being made by adult stem cell companies in addressing the significant unmet medical needs in degenerative conditions such as stroke and heart failure," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "For the past 7 years, we have been working on developing two types of adult stem cell therapies which are protected by issued US patents."
Our first type of technology is based on a more immediate commercialization, these therapies use the patient's own unexpanded and minimally manipulated stem cells, termed autologous stem cells, that can be rapidly implemented because of the long safety record of this type of procedure. Our CaverstemTM procedure, involves using the patient's own bone marrow derived stem cells to treat drug-resistant erectile dysfunction. This clinically tried procedure is already being performed by doctors on the West Coast.
Our second autologous bone marrow stem cell procedure for the treatment of degenerative disc disease, termed StemSpine™, is in the process of commercialization. Our second type of technology is a "universal donor" stem cell that is similar to stem cells developed by Athersys and Mesoblast. In contrast to other universal donor stem cell types, the stem cell developed by Creative Medical Technology Holdings, Inc., termed "AmnioStemTM is derived from amniotic fluid, which possesses a higher ability to regenerate tissues as compared to other stem cell types. Our AmnioStemTM, universal donor stem cell is being developed as a treatment for stroke, with an FDA Investigational New Drug Application (IND) filing planned to initiate clinical trials.
"I am very impressed with the speed, agility, and precision that the team at Creative Medical Technology Holdings has displayed in advancing both autologous and allogeneic stem cell therapies," said Dr. Santosh Kesari, MD, PhD, FANA, FAAN, Director of the Neuroscience Research Center at the Pacific Neuroscience Institute and Member of Creative Medical Technology Holdings, Inc. Scientific Advisory Board. "I look forward to working with the company in advancing its adult stem cell therapy products, which aim to address numerous unmet medical needs."
"Urologist to the Stars" Dr. Alexander Gershman Begins Treating Patients with Patented Caverstem™ Stem Cell Procedure for Drug Refractory Erectile Dysfunction
PHOENIX, and LOS ANGELES, Dec. 18, 2017
PHOENIX, and LOS ANGELES, Dec. 18, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today initiation of patient treatments using its patented Caverstem™ procedure by Dr. Alexander Gershman.
Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center, began treating patients with the procedure, which involves extraction of a small amount of bone marrow, concentration of bone marrow derived stem cells, and subsequent administration to the patient within less than an hour.
"There is much excitement about stem cells revolutionizing many aspects of medicine. I am enthusiastic to be offering this cutting edge procedure to my patients, for which previous therapies have failed or are too invasive," said Dr. Gershman. "Numerous publications and a recent clinical trial at the Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA, support the safety and feasibility of the Caverstem™ procedure. The biological basis of the bone marrow based treatment is that in patients with drug non-responsive erectile dysfunction, there is a deficit in function of smooth muscle and blood vessel cells. By administering the patient's own stem cells we aim to rebuild these damaged tissues, and thereby restore erectile function."
Creative Medical Health Technology Holdings is offering the Caverstem™ procedure to selected urologists in the USA, which qualify according to the Company's criteria. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
"We are pleased to have received such enthusiasm from one of the Opinion Leaders of the Urology community in the first 30 days of commercialization and anticipate similar responses as we expand our physician base throughout the United States" said Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction
PHOENIX, Oct. 19, 2017
PHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB – CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem™ procedure.
The trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval. An independent medical safety monitor was also appointed to review the patient data for safety and feasibility of administering bone marrow derived stem cells into patients with erectile dysfunction. The goal of this procedure is to regenerate blood vessels and smooth muscle, parts of the penis that are not functioning properly in this patient population.
"Based on establishment of safety of the CaverStem™ procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem™ procedure," said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. "Amongst other top urologists, we have recruited a world-renowned urologist as a lead physician to roll-out the procedure. We anticipate that the procedure will be available to patients that meet the eligibility criteria within the next 60 days."
According to the National Institutes of Health, approximately 30 million men in the United States suffer from Erectile Dysfunction2, of which 9 million do not respond to pharmacological treatments such as Viagra, Levitra and Cialis.
"The CaverStem™ procedure involves obtaining a small amount of bone marrow from the patient, purifying the stem cells using a closed system device that is FDA cleared, and then administering these cells in the same procedure into the patient's penis," said Thomas Ichim, Ph.D, Chief Scientific Officer and Co-Founder of the Company. "Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside."
Creative Medical Technology Holdings Expands Stem Cell Therapeutic Platform by Entry into Field of Stroke and Neurodegeneration
PHOENIX, Oct. 16, 2017
PHOENIX, Oct. 16, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB: CELZ) announced today filing of a patent application using a combination of an FDA approved drug together with the patient's own bone marrow derived stem cells for the treatment of stroke. The patent, entitled "Autologous Bone Marrow Mononuclear Cells as a Substrate for Enhancement of Neuroregenerative Therapy", covers the use of the patient's bone marrow stem cells, together with an FDA approved drug, to stimulate the naturally occurring regenerative processes after certain types of strokes. The Company has currently two issued patents using the patient's own bone marrow stem cells covering disc regeneration #9,598,673, and erectile dysfunction #8,372,797. The Company has recently reported completion of enrollment in its clinical trial for erectile dysfunction.
"Stroke represents one of those situations where the body's own stem cells leave the bone marrow, enter circulation, and attempt to heal the damaged brain areas. It is documented that patients in which larger numbers of bone marrow stem cells enter circulation, have a better prognosis as compared to patients in which stroke induces a lower number of stem cells to enter circulation1," said Thomas IchiIn the current patent we augment the naturally occurring approach by extracting stem cells from the bone marrow, placing them in circulation, and administering an FDA approved drug to enhance their activitym, Ph.D, Chief Scientific Officer of Creative Medical Technology Holdings. ". We are particularly excited by the fact that this approach falls under the practice of medicine and does not require full clinical trials for commercialization."
Creative Medical Technology Holdings focuses on rapid commercialization-based approaches using the patient's own stem cells under the practice of medicine.
"Stroke is a devastating condition, which is estimated to represent an over $20 billion dollar annual market in the USA alone. We are confident that our new approach to addressing stroke will provide a new tool in the hands of neurologists, which will allow for a 'natural-based' regenerative approach to this condition," said Timothy Warbington, President and Chief Executive Officer of the Company. "Given that we have been previously successful at having patents issued using autologous approaches, as well as our rapid entry into the clinic, we are excited to open up yet another market for our technology platform."
Creative Medical Technology Holdings Achieves 100% Patient Enrollment in CaverstemTM Clinical Trial for Stem Cell Treatment of Erectile Dysfunction
PHOENIX, Aug. 28, 2017
PHOENIX, Aug. 28, 2017 /PRNewswire/ -- Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today completion of enrollment in the Company's clinical trial assessing safety and efficacy of its CaverstemTM procedure to treat erectile dysfunction in patients who do not respond to currently available treatments. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
"The CaverstemTM procedure, which uses the patient's own bone marrow derived stem cells to induce arterial and venous regeneration, is an outpatient procedure able to be conducted by Urologists in their medical facilities. We are using a patient's own cells and we do not manipulate the stem cells through the use of chemicals, growth factors or expansion and have experienced no procedure-related safety issues," said Dr. Thomas Ichim Co-Founder and Chief Scientific Officer of Creative Medical Technology Holdings, Inc.
The clinical trial covering patients ages 18 to 80 received Institutional Review Board (IRB) approval in December 2016. The trial is sponsored by us based on our patented technology and is conducted by Dr. Jacob Rajfer, Principal Investigator and Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA.
"I am pleased with the expedience and efficiency at which enrollment was reached. As someone who regularly sees patients suffering from treatment non-responsive erectile dysfunction, I am excited to see the development of a novel approach to treating this condition using the patient's own natural regenerative processes," said Dr. Alexander Gershman, member of the Company's Scientific Advisory Board and Director of Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center."
"We are very fortunate to work with the expert team at Los Angeles Biomedical Institute - UCLA/Harbor Hospital who have done an outstanding job with subject recruitment, screening, treatment and follow-up. We firmly believe that we are on schedule for commercialization of the Caverstem TM procedure through publication and presentation of trial results, marketing, licensing, training and sales in 2018," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc. Files Patent on AmnioStem™ Mediated Immune Reprogramming for Stroke
PHOENIX and SAN DIEGO, May 24, 2017
PHOENIX and SAN DIEGO, May 24, 2017 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) (the "Company") announced today the filing of a patent application covering a novel means of suppressing inflammation associated with stroke by reprogramming immune cells of the stroke victim.
The patent application teaches ways of using the Company's patented AmnioStem™ allogeneic stem cell to 'educate' immune cells from stroke patients so as to reduce inflammation associated with stroke. By reducing inflammation, the Company hopes to develop novel means of increasing efficacy of therapeutic agents in stroke patients.
"We are highly enthusiastic with our current data, which seems to suggest that AmnioStem™cells are not only capable of inducing regeneration of injured brains, but also can be used to 'reprogram' immune system cells of patients in order to reduce inflammation that occurs subsequent to stroke," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "Working together with immunologists, neurologists, and stem cell experts, we are fortunate to have a team that can attack the problem of stroke in a multidisciplinary manner."
It is known that the immune system contributes to the deterioration of brain functions after a stroke. For example, studies in the mouse model of stroke have shown that if certain immune cells are depleted, the neurological impact of a stroke is diminished.1 It is also known that part of the therapeutic activities of stem cells in a stroke are mediated by alterations of the immune system.2
"We are confident that the novel findings presented in the patent application will pave the way for using AmnioStemTM treated patient immune cells as a means of suppressing pathological responses, which is applicable not only to strokes, but to a wide variety of neuroinflammatory conditions including multiple sclerosis and traumatic brain injuries," said Thomas lchim, Ph.D., Chief Scientific Officer of Creative Medical Technology Holdings.
1 Belinga et al. Splenectomy following MCAO inhibits the TLR4-NF-KB signaling pathway and protects the brain from neurodegeneration in rats. J Neuroimmunol. 2016 Apr 15; 293:105-13
2 Cheng et al. Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation. Brain Res. 2015 Jan 12;1594:293-304.
Stem Cell Technologies
Scientific Advisory Board